Comparison of Standard Neuronavigation With Intraoperative Magnetic Resonance Imaging (MRI) for the Neurosurgical Treatment of Malignant Brain Tumors (RACING)
Status
Conditions
Treatments
Details and patient eligibility
About
The treatment of a specific subtype of highly malignant brain tumor (called "glioblastoma" or "glioblastoma multiforme") consists of neurosurgical resection, followed by radiotherapy and mostly chemotherapy as well. Increased extent of tumor resection is associated with prolonged survival. The standard treatment uses conventional neuronavigation systems to increase extent of tumor resection. However, the quality of this form of neuronavigation decreases throughout surgery because of "brain shift". This is caused by edema, loss of cerebrospinal fluid and tumor resection. A new form of neuronavigation uses intraoperative MRI to compensate for brain shift, and to check for the presence of residual tumor that can be removed.
This study aims to compare the extent of glioblastoma resection between the standard treatment and intraoperative MRI.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- supratentorial brain tumor, on contrast enhanced dMRI suspected to be GBM
- indication for gross total resection (GTR) of the tumor
- age ≥18 years
- WHO Performance Scale ≤ 2
- ASA class ≤ 3
- adequate knowledge of the Dutch or French language
- informed consent
Exclusion criteria
- recurrent brain tumor
- multiple brain tumor localizations
- earlier skull radiotherapy
- earlier chemotherapy for GBM
- Chronic Kidney Disease or other renal function disorder
- known MR-contrast allergy
Trial design
Primary purpose
Allocation
Interventional model
Masking
14 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal